DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03022799 (ClinicalTrials.gov)	November 2016	27/12/2016	Phase I, KM-819 in Healthy Subjects for Parkinson's Disease	A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects	Parkinson's Disease	Drug: KM-819;Drug: Placebo	Kainos Medicine Inc.	NULL	Completed	19 Years	45 Years	All	88	Phase 1	Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03022799
(ClinicalTrials.gov)

November 2016

27/12/2016

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects

Parkinson's Disease

Drug: KM-819;Drug: Placebo

Kainos Medicine Inc.

NULL

Completed

19 Years

45 Years

All

Phase 1

Korea, Republic of